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Erythrocyte zinc protoporphyrin. In iron deficiency and lead of iron to or within bone marrow or that stimulates
poisoning, the enzyme ferrochelatase catalyzes the incorpora- porphyrin synthesis can potentially lead to an accumula-
tion of zinc, instead of iron, into protoporphyrin IX, resulting tion of ZPP [2]. During iron deficiency, not only is ZPPin the formation of zinc protoporphyrin (ZPP). In healthy
the product of iron-deficient erythropoiesis, but it alsoblood donors, there is a good inverse correlation between se-
inhibits heme oxygenase, thereby slowing heme catabo-rum ferritin and ZPP levels. In renal failure patients and in
patients with anemia caused by a variety of chronic disorders, lism and conserving heme. This might have a physiologi-
two different types of iron deficiency are found: (a) absolute cally beneficial function.
iron deficiency and (b) relative, or functional, iron deficiency.
The latter occurs when iron, despite adequate stores, is not
delivered rapidly enough to the erythroblasts. ZPP is not only METHODS OF ZINC PROTOPORPHYRINindicative of absolute iron deficiency, but it is also, for now,
MEASUREMENTthe best indicator of iron-deficient erythropoiesis, along with
the percentage of hypochromic red blood cells. By contrast, As mentioned earlier, in the past, methods to assay
serum ferritin and transferrin saturation may not adequately ZPP involved an acid extraction procedure that con-assess functional iron deficiency. Elevated ZPP levels in renal
verted ZPP to the metal-free protoporphyrin [3]. Laterfailure patients can be caused by different pathogenetic mecha-
on, high-performance liquid chromatography was usednisms, such as chronic inflammatory disease, lead poisoning,
and the presence of uremic factors, all of which could poten- to separate and measure metal-free protoporphyrin and
tially inhibit heme biosynthesis. However, ZPP levels do not ZPP fluorometrically [4]. Hematofluorometry was devel-
consistently predict an erythropoietic response to iron supple- oped as a consequence of the observation that directmentation in maintenance hemodialysis patients, and thus, iron
fluorometric determination, without prior acid extrac-overload during i.v. iron supplementation cannot be detected
by measuring ZPP. tion, of ZPP in whole blood was possible [5, 6].
Two types of hematofluorometer are commonly used:
The hematofluorometer (AVIV Biomedical, Lakewood,
Zinc protoporphyrin (ZPP) has been studied since NJ, USA) measures the ratio of ZPP fluorescence to heme
1930 in the metal-free protoporphyrin form because of absorption as a function of the amount of light emitted
the acid extraction procedure that was the technology by ZPP at 594 nm versus the amount of excitatory light
of that era. In 1974, Lamola and Yamane studied the absorbed by hemoglobin at 420 nm. The Proto Fluor
fluorescence of porphyrin in whole blood and thus were System (Helena Laboratories, Beaumont, TX, USA)
the first to identify ZPP as the predominant metabolite measures the molar ratio of ZPP to heme in the whole
[1]. Normally, ferrous iron is chelated to protoporphyrin blood after adding one drop of Protofluor reagent to
IX to form heme in a terminal reaction catalyzed by the one drop of whole blood. The reagent derivatizes hemo-
enzyme ferrochelatase. In either the absence of iron or globin, thereby avoiding falsely low results caused by the
inadequate delivery of iron to the enzymatic reaction, spectral shift that occurs with deoxygenated hemoglobin.
zinc is chelated by the same enzyme to protoporphyrin
IX, forming ZPP. ZINC PROTOPORPHYRIN IN
Iron-deficient erythropoiesis may occur in patients NONRENAL PATIENTS
with absolute iron deficiency as well as in patients with In 1979, after several years of use as a method to
adequate iron stores (functional iron deficiency). Any screen for lead exposure, Schifman et al started to study
pathological process or condition that limits the transfer the value of the red blood cell (RBC) ZPP test in screen-
ing for iron deficiency anemia in blood donors [7]. Zinc
can replace iron in the protoporphyrin ring, and theKey words: iron deficiency, anemia, lead poisoning, ferritin, erythropoi-
esis, blood cells. concentration of RBC ZPP rises when iron stores are
depleted. Consistent with this observation, they found a 1999 by the International Society of Nephrology
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direct relationship between yearly blood donation fre- rHuEPO because normal serum ferritin levels do not
exclude iron deficiency.quency and RBC ZPP values. Mean RBC ZPP in 15
nondeferred men was 46.0 mg/dl RBCs, and in 32 nonde- Garrett and Worwood compared the percentage of
hypochromic RBCs with ZPP levels as direct indicatorsferred women, it was 53.4 mg/dl RBCs (using a hemato-
fluorometer calibrated to measure RBC ZPP in mg/dl). of iron-deficient erythropoiesis [12]. There were three
patient groups: (a) patients with iron-deficient anemia,The greatest rise in ZPP levels was in those patients
donating blood two or three times a year. Furthermore, (b) patients with rheumatoid arthritis, and (c) patients
with chronic renal failure who were receiving erythropoi-Schifman et al noted an excellent correlation between
ferritin and RBC ZPP levels and, therefore, recom- etin therapy. Significant correlation between ZPP levels
and the percentage of hypochromic RBCs was found inmended using ZPP in screening other populations at risk
for iron-deficiency anemia [7]. renal failure patients; however, the ZPP levels were also
elevated in patients with hypochromic RBCs of less thanThe same group used RBC ZPP testing for iron-defi-
ciency anemia in pregnancy [8] and to evaluate anemia 5%. The median ZPP level in chronic renal failure pa-
tients was 90 mmol/mol heme, using the hematofluoro-risk in deferred blood donors [9].
In more than 4000 children between the ages of 6 meter from Helena Laboratories. The median value in
normal males was 40 mmol/mol heme, and in normalmonths and 12 years, Yip, Schwartz and Deinard found
the optimal cut-off value of the erythrocyte protoporphy- females it was 43 mmol/mol heme. The authors concluded
that high levels of the ZPP in renal failure patients with-rin test to be 35 mg/dl ZPP in whole blood [10]. The
specificity of the test was 90% and the sensitivity was out an elevated percentage of hypochromic RBCs may
indicate some interference with the assay in these pa-88%, however, the predictive value of low levels of serum
ferritin was 38%. The authors therefore concluded that tients. In addition, the high levels of ZPP in almost all
patients with chronic renal failure on maintenance HDelevated levels of ZPP can be regarded as evidence of
an inadequate supply of iron for hematopoiesis, regard- make it unlikely that ZPP levels will identify patients
with functional iron deficiency during rHuEPO therapyless of serum ferritin status. Moreover, individuals with
and iron supplementation. In contrast, Fishbane andthis finding may benefit from iron supplementation. Yip
Lynn found similar positive predictive values of ferritinet al also stated, however, that factors other than an
and ZPP for predicting a response to i.v. iron dextraninadequate supply of iron can influence heme biosynthe-
(73% vs. 83%, respectively) [13]. They investigated pa-sis and subsequently ZPP levels [10].
tients suspected of being iron deficient with ZPP of more
than 90 mmol/mol heme or ferritin of less than 100 ng/
ZINC PROTOPORPHYRIN IN ml. They chose a ZPP value of 90 mmol/mol heme, as
RENAL PATIENTS this concentration appeared to be the best cut-off point
Hastka et al used the determination of ZPP as a in their population. Although iron was given only to
screening method for assessment of iron deficiency in patients with ZPP of more than 90 mmol/mol heme and
maintenance hemodialysis (HD) patients [11]. They ferritin of less than 100 ng/ml, it is possible that some
compared a group of 32 recombinant human erythropoi- of the other patients could have also responded to iron
etin (rHuEPO) treated patients with i.v. iron supplemen- supplementation. Nonetheless, the sensitivity and speci-
tation and serum ferritin of more than 200 ng/ml with ficity reported for ZPP are valid for this particular group
a group of 30 rHuEPO treated patients with i.v. iron of patients only. Baldus et al investigated the parameters
supplementation and serum ferritin of only less than 50 hemoglobin, hematocrit, mean corpuscular volume, iron,
ng/ml. The rHuEPO doses in both groups were compara- ferritin, transferrin saturation, and ZPP in 113 HD pa-
ble (93 6 36 IU/kg body wt/week vs. 99 6 51 IU/kg body tients [14]. In 39 patients (33.3%), they found discrepant
wt/week).The ZPP levels were significantly lower (41.7 6 results: ZPP was elevated in 16 patients (13.6%) but
12.5 mmol/mol heme vs. 82.2 6 37.4 mmol/mol heme) and transferrin saturation was in the normal range, whereas
the hemoglobin levels were significantly higher (10.4 6 in 23 patients (19.6%) the opposite results were ob-
1.7 g/dl vs. 8.9 6 1.0 g/dl) in group 1 than in group 2. served. As they found no correlation between ZPP and
The authors concluded that patients with ZPP of more any other of the investigated parameters, they concluded
than 50 mmol/mol heme should be treated with iron that beyond the upper limits of manifest iron storage
independent of the serum ferritin level prior to rHuEPO deficiency, defined as ferritin of less than 30 ng/ml in
therapy. After six months of iron supplementation, ZPP males and less than 15 ng/ml in females, ZPP and trans-
levels decreased from 118.6 6 14.1 mmol/mol heme to ferrin saturation describe different ranges of functional
66.4 6 23.0 mmol/mol heme in 10 patients with ZPP of iron deficiency. We studied 62 patients on maintenance
more than 100 mmol/mol heme at the beginning of the HD with ZPP levels of more than 50 mmol/mol heme,
therapy. It was further recommended that serum ferritin assessing the value of ZPP as a marker of functional iron
deficiency at different cut-off points of ZPP [15]. In 148levels should be at least 200 ng/ml before treating with
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Table 1. Combination of the parameters ferritin, zinc protoporphyrin (ZPP) and hypochromic red blood cells (RBC)
and the assessment of iron status in hemodialysis patients
Ferritin Zinc protoporphyrin Hypochromic RBC,
lg/liter lmol /mol heme % Assessment of iron status
,100 ,90 ,5 DIS, no IDE
,100 ,90 .5 DIS, early state of IDE
,100 .90 .5 DIS, chronic state of IDE, infection
,100 .90 ,5 DIS, early phase of treatment of IDE
.100 ,90 ,5 no DIS, no IDE
.100 ,90 .5 no DIS, early state of IDE, infection
.100 .90 .5 no DIS, IDE, infection, other pathological factors
.100 .90 ,5 no DIS, early phase of treatment of IDE, infection, other pathological factors
Abbreviations are: DIS, decreased iron store; IDE, iron deficient erythropoiesis.
HD patients without inflammatory disease or malig- tion at the beginning of the study, which could have been
useful in predicting the erythropoietic response. Thisnancy, the mean ZPP level was 76.4 6 49.7 mmol/mol
heme, and there was a clearly right-sided tail reflecting finding was independent of the ZPP cut-off in the range
of 50 to 110 mmol/mol heme. Cove-Smith compared ZPPthe generally higher ZPP levels in these patients. We
found no significant change in ZPP levels after iron sup- and ferritin in a cross-sectional design in 78 HD and
28 continuous ambulatory peritoneal dialysis patients toplementation in patients with a ZPP of more than 50
mmol/mol heme (96.7 6 49.8 vs. 88.4 6 43.5 mmol/mol determine which assay reliably detects iron deficiency
[16]. No significant correlation between ZPP and ferritinheme) before and after iron administration of 960 mg
within six months. Only in patients with ZPP of more was seen. Serum ferritin reflected iron loading better
than ZPP, but neither variable consistently predicted anthan 90 mmol/mol heme did i.v. iron supplementation
lead to a significant reduction of ZPP (141.2 6 54.5 vs. erythropoietic response to iron supplementation.
In a second study, we also found no correlation be-108.0 6 48.8 mmol/mol heme, P , 0.001).
Additionally, we found significantly lower ZPP levels tween ZPP levels and the percentage of hypochromic
RBCs at any time [17]. However, the median ZPP levelsin those patients with total blood lead concentrations of
less than 200 ng/ml than in those patients with higher declined rather uniformly after the intensified i.v. iron
supplementation (800 mg iron per patient within 12lead concentrations (86.1 6 38.1 vs. 115.5 6 65.8 mmol/
mol heme, P , 0.05). The linear correlation between weeks): in patients with RBCs of less than 5% from 47
mmol/mol heme (range 4 to 282 mmol/mol heme) to 35.5the moderately elevated total blood lead concentrations
found in these patients and the ZPP levels does not mmol/mol heme (range 10 to 257 mmol/mol heme), in
patients with hypochromic RBC levels between 5% andimply a cause and effect relationship, but elevated lead
concentrations may contribute to the disturbed erythro- 10% from 49.0 mmol/mol heme (range 1 to 122 mmol/mol
heme) to 40.5 mmol/mol heme (range 13 to 117 mmol/poiesis. Iron deficiency seems to be an additional contrib-
utor to increased ZPP levels in those patients with ZPP mol heme), and in patients with hypochromic RBCs
more than 10% from 59.0 mmol/mol heme (range 3 tolevels of more than 90 mmol/mol heme, whereas in pa-
tients with ZPP levels of less than 90 mmol/mol heme, 386 mmol/mol heme) to 51.0 mmol/mol heme (range 13
to 255 mmol/mol heme). Again, we found comparableZPP levels remain unchanged during iron supplementa-
tion. Our results support those of Fishbane and Lynn, ZPP levels at baseline and at the end of the study, and
there was no difference between rHuEPO-treated pa-who considered HD patients with ZPP levels of more
than 90 mmol/mol heme and serum ferritin levels of less tients and patients not receiving rHuEPO. These data
are comparable to those of Garrett and Worwood, whothan 100 ng/ml to be iron deficient [13]. These investiga-
tors found that among patients with ferritin higher than found that ZPP levels in 40 chronic renal failure patients
receiving dialysis and erythropoietin therapy were 68 to100 ng/ml but ZPP more than 90 mmol/mol heme, 7 out
of 10 patients (70%) responded positively to therapy 180 mmol/mol heme (they omitted one patient with a
value of 693 mmol/mol heme) [12]. Only seven of the 39with i.v. iron (a sustained 5% increase of hematocrit or
a decrease of rHuEPO dose of more than 2000 IU per patients had a percentage of hypochromic RBCs of more
than 5% as a sign of iron-deficient erythropoiesis. Threetreatment). In our patients with ZPP of more than 90
mmol/mol heme, a positive response was noted in 11 of of these seven patients had ZPP levels of less than 100
mmol/mol heme. However, seven patients with a percent-24 (45%), but we also found positive reactions in 30 of
62 (48%) patients with ZPP levels of more than 50 mmol/ age of the hypochromic RBCs less than 5% had ZPP
levels of more than 100 mmol/mol heme.mol heme. ZPP levels were not significantly different in
responders and nonresponders to i.v. iron supplementa- Table 1 shows the possible combinations of the param-
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eters of serum ferritin, ZPP, the percentage of hypochro- account other pathological factors and not simply at-
tempt to interpret ZPP as an isolated test result [19].mic RBC, and an assessment of iron status. ZPP and
the percentage of hypochromic RBC determine iron-
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